# Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy

Study · id `cardio:ct-nct01893788` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01893788](<https://clinicaltrials.gov/study/NCT01893788>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01893788

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT01893788. Randomized; no masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2016-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT01893788, source copy `cardio:ctgov-nct01893788-2013-07-22`, retrieved 2026-10-26)
- Start date: 2013-04 (registry gives no type) (ClinicalTrials.gov record NCT01893788, source copy `cardio:ctgov-nct01893788-2013-07-22`, retrieved 2026-10-26)
- Primary completion: 2016-03 (anticipated) (ClinicalTrials.gov record NCT01893788, source copy `cardio:ctgov-nct01893788-2013-07-22`, retrieved 2026-10-26)
- Completion: Not reported
- Countries: Japan (ClinicalTrials.gov record NCT01893788, source copy `cardio:ctgov-nct01893788-2013-07-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01893788-2013-07-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy
- Acronym: EARTH
- Condition: Hypertensive Left Ventricular Hypertrophy
- Intervention (Drug): Aliskiren
- Intervention (Drug): Eplerenone
- Lead sponsor: Nagoya University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: eaa952f60c1f90b3424233ae623dd4634588b124a562da93f7e03e584bf991a5
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
